Exhibitors Search
DXY (GUANLAN NETWORKS (HANGZHOU) CO., LTD.) Li Sha / Director
Booth no.
P70
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| |
|
Address
|
|4F, DXY Center T1, No. 723 Chaoyong Road, Binjiang District |
|
Tel
|
| |
|
Exhibits
|
| Digital Health & Medical Data Platform for Healthcare Professionals and the Healthcare Industry |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup , Digital Health / Medical Device Company , CRO / CMO Company |
Exhibitor Information
DXY is China's foremost digital health technology company. Since founding in 2000, DXY has garnered 9 million registered healthcare professionals ? around 80% of China's medical workforce, including 4.05 million licensed physicians, representing around 92% of all licensed physicians in China.
Founded in 2006, DXY Insight Database is a global pharmaceutical data intelligence and analytics platform developed by DXY. With 20 years' continuous development in the pharmaceutical sector, we serve 3,000+ enterprises across the full industry value chain, including pharmaceutical companies, investment firms, and pharmaceutical service providers.
We are trusted by leading industry players, including 92% of MNCs and 75% of China’s Top 100 pharmaceutical enterprises. As a long-term data partner to the industry, it enables organizations to quickly understand competitive landscapes, identify emerging opportunities, and make more informed decisions in new drug R&D strategy and pipeline development.
Founded in 2006, DXY Insight Database is a global pharmaceutical data intelligence and analytics platform developed by DXY. With 20 years' continuous development in the pharmaceutical sector, we serve 3,000+ enterprises across the full industry value chain, including pharmaceutical companies, investment firms, and pharmaceutical service providers.
We are trusted by leading industry players, including 92% of MNCs and 75% of China’s Top 100 pharmaceutical enterprises. As a long-term data partner to the industry, it enables organizations to quickly understand competitive landscapes, identify emerging opportunities, and make more informed decisions in new drug R&D strategy and pipeline development.
Exhibit Description
DXY Insight Database provides global pharmaceutical full-lifecycle data with deep China insights, which is 100% verifiable and fully traceable. We aim to engage with potential partners, including pharmaceutical companies, biotech innovators, investment institutions and consulting firms, who seek to make more precise decisions and work more efficiently, particularly in BD and transaction decision-making.
We enable partners to gain comprehensive visibility into global drug pipelines and competitive landscapes, and to identify and evaluate high-value assets across therapeutic areas. By integrating multi-dimensional insights, users can better assess in-licensing and out-licensing opportunities and improve the efficiency and accuracy of BD evaluation and strategic partnering decisions.
We enable partners to gain comprehensive visibility into global drug pipelines and competitive landscapes, and to identify and evaluate high-value assets across therapeutic areas. By integrating multi-dimensional insights, users can better assess in-licensing and out-licensing opportunities and improve the efficiency and accuracy of BD evaluation and strategic partnering decisions.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : DXY Insight DatabaseFounded in 2006, DXY Insight Database is a global pharmaceutical data intelligence and analytics platform developed by DXY. With 20 years of continuous development in the pharmaceutical sector, we serve 3,000+ enterprises across the full industry value chain, including pharmaceutical companies, investment institutions, and pharmaceutical service providers. Today, DXY Insight Database is trusted by leading industry players, including 92% of MNC pharma companies and 75% of China’s Top 100 pharmaceutical enterprises. As a long-term data partner to the industry, it enables organizations to quickly understand competitive landscapes, identify emerging opportunities, and make more informed decisions in new drug R&D strategy and pipeline development.
KYUNGYON EXHIBITION CORP.
